Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Colorectal Neoplasms 112Breast Neoplasms 87Carcinoma, Non-Small-Cell Lung 85Glioblastoma 72Ovarian Neoplasms 62Brain Neoplasms 45Lung Neoplasms 41Glioma 41Fallopian Tube Neoplasms 41Neoplasms 38Colonic Neoplasms 34Gliosarcoma 33Carcinoma, Renal Cell 32Rectal Neoplasms 31Neoplasm Metastasis 29Pancreatic Neoplasms 19Carcinoma, Hepatocellular 19Melanoma 18Adenocarcinoma of Lung 18Astrocytoma 15Kidney Neoplasms 13Stomach Neoplasms 12Prostatic Neoplasms 12Uterine Cervical Neoplasms 11Oligodendroglioma 11Liver Neoplasms 11Esophageal Neoplasms 11Sarcoma 10Adenocarcinoma, Bronchiolo-Alveolar 10Central Nervous System Neoplasms 9

Interventions

cobimetinib 1atezolizumab 1Taxes 1Paclitaxel 1Immunoglobulin G 1Gemcitabine 1Docetaxel 1Disulfides 1Carboplatin 1Bevacizumab 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Adenocarcinoma, Mucinous × Bevacizumab × Clear all
NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,052 enrolled 27 charts
Gynecologic

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡